JP6062432B2 - プロテインキナーゼ阻害薬用スピロ環状分子 - Google Patents

プロテインキナーゼ阻害薬用スピロ環状分子 Download PDF

Info

Publication number
JP6062432B2
JP6062432B2 JP2014521885A JP2014521885A JP6062432B2 JP 6062432 B2 JP6062432 B2 JP 6062432B2 JP 2014521885 A JP2014521885 A JP 2014521885A JP 2014521885 A JP2014521885 A JP 2014521885A JP 6062432 B2 JP6062432 B2 JP 6062432B2
Authority
JP
Japan
Prior art keywords
group
cancer
ring
membered
dichloro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2014521885A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014521609A (ja
JP2014521609A5 (enExample
Inventor
ワン，ツァオイン
リー，リャンハイ
ワン，チーガン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nanjing Allgen Pharma Co Ltd
Original Assignee
Nanjing Allgen Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanjing Allgen Pharma Co Ltd filed Critical Nanjing Allgen Pharma Co Ltd
Publication of JP2014521609A publication Critical patent/JP2014521609A/ja
Publication of JP2014521609A5 publication Critical patent/JP2014521609A5/ja
Application granted granted Critical
Publication of JP6062432B2 publication Critical patent/JP6062432B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2014521885A 2011-07-27 2012-07-26 プロテインキナーゼ阻害薬用スピロ環状分子 Expired - Fee Related JP6062432B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161457980P 2011-07-27 2011-07-27
US61/457,980 2011-07-27
PCT/CA2012/000709 WO2013013308A1 (en) 2011-07-27 2012-07-26 Spirocyclic molecules as protein kinase inhibitors

Publications (3)

Publication Number Publication Date
JP2014521609A JP2014521609A (ja) 2014-08-28
JP2014521609A5 JP2014521609A5 (enExample) 2015-09-10
JP6062432B2 true JP6062432B2 (ja) 2017-01-18

Family

ID=47600420

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014521885A Expired - Fee Related JP6062432B2 (ja) 2011-07-27 2012-07-26 プロテインキナーゼ阻害薬用スピロ環状分子

Country Status (6)

Country Link
US (1) US9226923B2 (enExample)
EP (1) EP2739617A4 (enExample)
JP (1) JP6062432B2 (enExample)
CN (1) CN103732588B (enExample)
CA (1) CA2842841C (enExample)
WO (1) WO2013013308A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201605791A (zh) 2013-09-26 2016-02-16 美涅莫辛製藥公司 Ｎｒ２ｂ之選擇性八氫-環戊二烯并［ｃ］吡咯負向調節劑
WO2018166855A1 (en) 2017-03-16 2018-09-20 Basf Se Heterobicyclic substituted dihydroisoxazoles
US20220143049A1 (en) 2019-03-21 2022-05-12 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
PE20221453A1 (es) 2019-10-09 2022-09-21 Novartis Ag Derivados de 2-azaspiro[3,4]octano como agonistas de m4
CN119390705A (zh) 2019-10-09 2025-02-07 诺华股份有限公司 作为m4激动剂的5-氧杂-2-氮杂螺[3.4]辛烷衍生物
EP4054579A1 (en) 2019-11-08 2022-09-14 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021120890A1 (en) * 2019-12-20 2021-06-24 Novartis Ag Pyrazolyl derivatives useful as anti-cancer agents
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60001623T2 (de) * 1999-12-03 2003-12-18 Pfizer Products Inc., Groton Sulfamoylheteroarylpyrazolverbindungen zur Verwendung als analgetisches/entzündungshemmendes Mittel
MXPA05009063A (es) * 2003-02-26 2005-12-12 Sugen Inc Compuestos de aminoheteroarilo como inhibidores de proteina cinasa.
WO2006021886A1 (en) * 2004-08-26 2006-03-02 Pfizer Inc. Aminoheteroaryl compounds as protein tyrosine kinase inhibitors
ES2355923T3 (es) * 2004-08-26 2011-04-01 Pfizer, Inc. Compuestos de aminoheteroarilo sustituidos con pirazol como inhibidores de proteina quinasa.
CA2646701A1 (en) * 2006-03-22 2007-10-04 Vertex Pharmaceuticals Incorporated C-met protein kinase inhibitors for the treatment of proliferative disorders
CA2703653A1 (en) * 2007-10-25 2009-04-30 Astrazeneca Ab Pyridine and pyrazine derivatives -083
WO2009099982A1 (en) * 2008-02-04 2009-08-13 Osi Pharmaceuticals, Inc. 2-aminopyridine kinase inhibitors
EP2432779A1 (en) * 2009-05-22 2012-03-28 Exelixis, Inc. Benzoxazepines based p13k/mt0r inhibitors against proliferative diseases
CN101851237B (zh) * 2010-06-18 2012-10-17 南方医科大学 一种螺环化合物及其制备方法和应用
WO2013148537A1 (en) * 2012-03-29 2013-10-03 Ning Xi Substituted spirobicyclic compounds and methods of use

Also Published As

Publication number Publication date
WO2013013308A1 (en) 2013-01-31
JP2014521609A (ja) 2014-08-28
CN103732588A (zh) 2014-04-16
CA2842841A1 (en) 2013-01-31
EP2739617A4 (en) 2015-01-28
US9226923B2 (en) 2016-01-05
CA2842841C (en) 2016-04-19
EP2739617A1 (en) 2014-06-11
CN103732588B (zh) 2016-10-12
US20140243303A1 (en) 2014-08-28

Similar Documents

Publication Publication Date Title
US9650358B2 (en) Pyridine CDK9 kinase inhibitors
JP5985658B2 (ja) ブルトンチロシンキナーゼ阻害薬としての環状分子
JP6371430B2 (ja) ブロモドメイン阻害薬
CN101573358B (zh) 吡啶并(2,3-d)嘧啶酮化合物及其作为pi3抑制剂的用途
JP6062432B2 (ja) プロテインキナーゼ阻害薬用スピロ環状分子
CN107849012B (zh) 一类激酶抑制剂
CN102985422A (zh) 激酶的吡咯并吡啶和吡咯并嘧啶抑制剂
CN104039797B (zh) 作为细胞凋亡诱导剂的杂环分子
CA2901929A1 (en) Cdk9 kinase inhibitors
CN111454268B (zh) 作为布鲁顿酪氨酸激酶抑制剂的环状分子
WO2014160028A1 (en) Pyrrolopyrimindine cdk9 kinase inhibitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150724

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150724

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20160310

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160324

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160624

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160816

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20161202

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20161214

R150 Certificate of patent or registration of utility model

Ref document number: 6062432

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees